AC Immune (NASDAQ:ACIU) Rating Lowered to Sell at Zacks Investment Research

AC Immune (NASDAQ:ACIU) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

Other analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of AC Immune from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. TheStreet downgraded shares of AC Immune from a “c” rating to a “d+” rating in a research note on Tuesday, May 12th. Finally, ValuEngine cut AC Immune from a “buy” rating to a “hold” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $9.75.

NASDAQ:ACIU opened at $6.73 on Monday. The company has a market capitalization of $456.05 million, a PE ratio of -17.71 and a beta of 0.52. AC Immune has a 52-week low of $4.07 and a 52-week high of $10.14. The stock’s 50 day moving average price is $7.17 and its 200 day moving average price is $7.64. The company has a quick ratio of 21.28, a current ratio of 21.28 and a debt-to-equity ratio of 0.01.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. The business had revenue of $12.83 million during the quarter, compared to the consensus estimate of $10.30 million. AC Immune had a negative return on equity of 8.71% and a negative net margin of 52.68%. As a group, sell-side analysts anticipate that AC Immune will post -0.92 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in the company. State of Tennessee Treasury Department purchased a new position in AC Immune during the fourth quarter worth about $32,000. Citigroup Inc. increased its position in AC Immune by 194.8% during the 4th quarter. Citigroup Inc. now owns 5,239 shares of the company’s stock worth $45,000 after purchasing an additional 3,462 shares during the period. New York State Common Retirement Fund increased its position in AC Immune by 35.7% during the 4th quarter. New York State Common Retirement Fund now owns 8,244 shares of the company’s stock worth $70,000 after purchasing an additional 2,168 shares during the period. Mackenzie Financial Corp purchased a new position in shares of AC Immune during the 1st quarter worth approximately $77,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of AC Immune in the 1st quarter valued at approximately $81,000. Institutional investors own 29.84% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Recommended Story: Conference Calls and Individual Investors

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.